Welcome to InfiCure Bio
InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.
Based on a panel of in vivo models for these conditions including a proprietary model, the NIF mouse, for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.
Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.
News
InfiCure Bio is part of the Catalyst program
InfiCure Bio has been accepted to Business Swedens Catalyst program, which is a program aimed at helping companies scale globally. The focus for InfiCure Bio is the Korean market and Business Sweden will help InfiCure to [...]
InfiCure Bio presenting at LSX Nordic
The CEO of InfiCure Bio presented the company at LSX Nordics in Stockholm on August 28th. To watch the presentation click here.
LSX Nordic Congress
InfiCure Bio will be presenting at the LSX Nordic Congress in Stockholm on August 28th. The company will be presenting during the start up showcase as one of the growth stage private companies.
Additional funding
InfiCure Bio has received additional funding from NLC InfiCure Bio and Partnerinvest Övre Norrland to speed up the validation of additional indications in the NIF mouse. This is a golden opportunity to broaden our customer [...]